Aaron Bussey, MD
Endocrinology, Diabetes & Metabolism · Maryville, TNNPI 1982672986
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 22.3%. Reporting peaked in 2020 at $9,528 and has fallen 68.2% since, to $3,026 in 2025.
Across 878 payments — averaging $39.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Sanofi-aventis U.S. LLC$7K
- Tandem Diabetes Care, Inc.$6K
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Mannkind Corporation$1K
- plus $9K from 48 others
What the payments were for
- Consulting fees$2,3107%
- Speaking & faculty fees$16,74848%
- Food & beverage$15,76545%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$7,375
- t:slim X2 insulin pump$3,950
- DISEASE STATE$2,310
- TOUJEO$2,210
- SOLIQUA 100/33$1,938
- t-slim insulin pump$1,400
- AFREZZA$236
- CeQur Simplicity$130
- Vascepa$121
- Minimed 670G System$114
- MOUNJARO$105
How this compares
$34,858 in reported general payments places this provider in the 80th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 27 | $72,009 |
| MounjaroTirzepatide | 37 | $49,909 |
| ForteoTeriparatide | 11 | $46,707 |
| OzempicSemaglutide | 36 | $46,616 |
| Teriparatide | 13 | $45,642 |
| JardianceEmpagliflozin | 29 | $37,721 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 14 | $33,043 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $30,150 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $16,081 |
| FarxigaDapagliflozin Propanediol | 11 | $14,523 |
| Novolog FlexpenInsulin Aspart | 22 | $7,688 |
| Levothyroxine Sodium | 590 | $4,983 |
| SynthroidLevothyroxine Sodium | 59 | $3,345 |
| Hydrocortisone | 64 | $2,915 |
| Testosterone | 21 | $2,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo | $2,291 | $96,61648 claims |
| Radius Health, Inc.Tymlos | $237 | $72,00927 claims |
| Novo NordiskOzempic | $1,610 | $46,61636 claims |
| Boehringer IngelheimJardiance | $327 | $37,72129 claims |
| AmgenEvenity (2 Syringes) | $861 | $33,04314 claims |
| AstraZenecaFarxiga | $7,769 | $14,52311 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $135 | $4,983590 claims |
| AbbVieSynthroid | $78 | $3,34559 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Maryville
- Sarah SmithMaryville$20K
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Pascal DauphinHendersonville$925K
- Shimon HararyMemphis$735K
- Lisa MyersGermantown$609K
- Amit VoraKnoxville$579K
- Terri JerkinsNashville$567K
- Samuel Dagogo-JackMemphis$407K
- Michael CarlsonNashville$381K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.